

# European LeukemiaNet Clinical Signs and Symptoms as Prognostic Markers in Polycythemia Vera During Ruxolitinib

Francesca Palandri<sup>1</sup>, Elena Rossi<sup>2,3</sup>, Massimo Breccia<sup>4</sup>, Elena M. Elli<sup>5</sup>, Chiara Sartor<sup>1</sup>, Alessandra Dedola<sup>1,6</sup>, Alessandra Iurlo<sup>7</sup>, Erika Morsia<sup>8</sup>, Novella Pugliese<sup>9</sup>, Roberto Latagliata<sup>10</sup>, Francesco Mendicino<sup>11</sup>, Alessia Tieghi<sup>12</sup>, Giulia Benevolo<sup>13</sup>, Gianni Binotto<sup>14</sup>, Mirko Farina<sup>15</sup>, Alessandra D'Addio<sup>16</sup>, Mario Tiribelli<sup>17</sup>, Daniela Cilloni<sup>18</sup>, Monica Crugnola<sup>19</sup>, Flavia Salvatore<sup>1,6</sup>, Filippo Branzanti<sup>1\*</sup>, Daniele Cattaneo<sup>7</sup>, Fabrizio Cavalca<sup>5</sup>, Emilia Scalzulli<sup>4</sup>, Fabrizio Pane<sup>9</sup>, Francesco Lanza<sup>16</sup>, Florian H. Heidel<sup>20</sup>, Giuseppe A. Palumbo<sup>21</sup>, Valerio De Stefano<sup>2,3</sup>

- 1) IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
- 2) Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy
- 3) Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
- 4) Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy
- 5) Fondazione IRCCS San Gerardo dei Tintori, Divisione di ematologia e unità trapianto di midollo, Monza, Italy
- 6) Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
- 7) Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 8) Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
- 9) Department of Clinical Medicine and Surgery, Hematology Section, University of Naples "Federico II", Naples, Italy
- 10) Hematology Unit, Ospedale Belcolle, Viterbo, Italy
- 11) U.O.C. di Ematologia, Department of Hemato-Oncology, Azienda Ospedaliera Annunziata, Cosenza, Italy
- 12) Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
- 13) University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy
- 14) Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy
- 15) Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- 16) Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy
- 17) Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy
- 18) Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
- 19) Haematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
- 20) Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
- 21) Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy

## Correspondence to:

Filippo Branzanti

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Istituto di Ematologia "Seràgnoli"

Via Massarenti 9

40138 Bologna, Italy


Email: [filippo.branzanti2@unibo.it](mailto:filippo.branzanti2@unibo.it)

Supplemental Table 1: Details of Thrombotic Events and distribution in Patients with Clinical Sign and Symptoms and in High-Risk Patients

Thrombosis type	Thrombosis Grade	Thrombosis Site	Thrombosis no.	CSS		High risk	
				<i>n (%)</i>	<i>IR (%p-y)</i>	<i>n (%)</i>	<i>IR (%p-y)</i>
Arterial thrombosis	≥3	Cerebral	1	1 (100)	0.23	1 (100)	0.16
Venous thrombosis	2	Limbs	2	2 (100.0)	0.46	1 (50.0)	0.16
	≥3	Limbs	3	3 (100)	0.69	3 (100)	0.47
		Pulmonary	1	1 (100)	0.23	1 (100)	0.16
		Splanchnic	1	1 (100)	0.23	1 (100)	0.16

Supplemental Table 1: CSS, Clinical Sign and Symptoms; RUX, ruxolitinib; n, number; IR, incidence rate; %p-y, per 100 patients-year

Supplemental Figure 1: Impact of Individual Clinical Signs and Symptoms on Thrombotic (A) and Progression (B) Risk during ruxolitinib



Supplemental Figure 1: HR, hazard ratio; CI, confidence interval; RUX, ruxolitinib